# Innoven Partners

> Innoven Partners is a VC fund in Paris backing Medical and Biotechnology. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 8
- Last investment: Jul 2011
- Lead investor: 25%
- Last updated: Aug 2026
- Website: http://www.innoven-partners.com

Innoven Partners is a VC fund in Paris focused on Medical and Biotechnology. Innoven Partenaires is a leading European venture capital firm, founded in 1998, managed by an international and experienced team with acknowledged know-how.

## Contacts

5 contacts available for Innoven Partners. Shizune tracks 8 team members at Innoven Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/innoven-partenaires?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 38% |
| Biotechnology | 3 | 38% |
| Health Care | 2 | 25% |
| Apps | 1 | 13% |
| Music | 1 | 13% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 4 | 50% |
| Series D | 2 | 25% |
| Series A | 1 | 13% |
| Series B | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 4 | 50% |
| Germany | 2 | 25% |
| United States | 1 | 13% |
| United Kingdom | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ben Kouakou | Investment Analyst | 0 | — |
| Claude-Audrey Picard | Investment Assistant | 0 | — |
| Gilles Michat | Member of the Supervisory Board | 0 | — |
| Jean-François Court | Vice-President of the Supervisory Board | 0 | https://shizune.co/investors/profile/jean-franois-court |
| Jean-Michel Paulhac | Management Board President | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SpineVision | SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed incollaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents.SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States. | $5M |  | Jul 06, 2011 |  |
| Club Cooee | Club Cooee is a 3D social network where millions of users from all over the world meet and connect in user-generated rooms. Users chat, party, DJ, dance, run music clubs, quiz, dress-up, design, sell their own creations and hang out with friends.Located in Kaiserslautern, Germany, Club Cooee is backed by venture investors Aurelia PrivateEquity, Generis Capital Partners, IPSA and ISB. |  | Series B | Oct 27, 2010 |  |
| Kiora Pharmaceuticals | EyeGate Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system. It is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGateÂII. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both pre-clinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease. |  | Series D | Jan 08, 2010 |  |
| BioVex | BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death ofcancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur. | $40M |  | Mar 30, 2009 |  |
| Monte Cristo | Created in Paris in 1995, Monte Cristo is a European PC and console game producer. They have released over 30 titles. In 2005 Monte Cristo set up an office in Kiev, Ukraine, in order to deploy the team sizes required for future production with greater ease. They are in development of a city-building MMO entitled Cities XL. | $7M |  | Jul 14, 2008 |  |
| Diatos | Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA.Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improvedbiodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP). | $12.8M | Series D | Jul 03, 2007 |  |
| In-Fusio | With the largest market share of mobile games in Europe and China and rapidly expanding presence in the U.S., IN-FUSIO offers a diverse portfolio of games, entertainment and value added services to wireless carriers. At present, IN-FUSIO's 65 mobile titles have been enjoyed by 11 million players worldwide. From stand-alone Java(TM), BREW andi-mode (Doja) games to a fully managed and integrated games service, (ExEn, ExEn Gaming Extensions EGE for Java MIPD 2.0) IN-FUSIO has unparalleled industry experience. As a games publisher and game service provider, IN-FUSIO is a clear entry point for brands and game developers to effortlessly enter the mobile market.IN-FUSIO customers include Verizon, Sprint, AT&T, Vodafone D2, Orange France, SFR, Orange UK, Vodafone Omnitel, Telefonica Moviles and China Mobile. The company currently has offices in Los Angeles, Chicago, London, Bordeaux, Moscow and Shanghai. | $27M |  | Aug 04, 2004 |  |
| gate5 | Gate5 offers mapping and location based services for mobile devices. The company was acquired by Nokia in 2006. | $7.1M | Series A | Mar 01, 2004 |  |

8 of 8 investments shown.

## Co-investors
- [Generis Capital Partners](https://shizune.co/investors/profile/generis-capital-partners) — VC Fund, 2 deals together
- [Ventech](https://shizune.co/investors/profile/ventech-capital) — VC Fund, 2 deals together
- [180 Degree Capital](https://shizune.co/investors/profile/180-degree-capital) — VC Fund, 1 deal together
- [360 Capital](https://shizune.co/investors/profile/360-capital-partners) — VC Fund, 1 deal together
- [Arts Alliance](https://shizune.co/investors/profile/arts-alliance) — VC Fund, 1 deal together
- [Aurelia Private Equity](https://shizune.co/investors/profile/aurelia-private-equity) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Innoven Partners invest in?

Innoven Partners invests primarily in Medical, Biotechnology and Health Care startups, most often at Funding Round and Series D stage. Most of the 8 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Innoven Partners?

Public channels for Innoven Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Innoven Partners?

The team at Innoven Partners includes Ben Kouakou (Investment Analyst), Claude-Audrey Picard (Investment Assistant) and Gilles Michat (Member of the Supervisory Board), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co